Results 1 to 10 of 66

Thread: RU58841 Warning

Threaded View

  1. #1
    Junior Member
    Join Date
    Oct 2014
    Posts
    2

    Default RU58841 Warning

    A low percentage of people have experienced heart pressure/pain and/or shortness of breath after using RU58841 after as little as one week of topical usage.

    Although rare, if you experience heart discomfort, pressure, and/or pain, discontinue use immediately, as in rare cases it can cause heart failure (it's a similar drug to nilutamide).

    Interstitial pneumonititis is a more common side effect of using DHT-blockers in the class of RU58841 and nilutamide. This is a serious lung condition, which can be triggered by certain medications (among other things). If left untreated, it can lead to permanent scarring of the lungs, such that you can no longer breath and can possibly die. However, in the vast majority of cases, the damage is fully reversed within 6 to 12 months of discontinuation of the drug. In severe cases, you'll need to take prednisolone along with discontinuing the drug.

    The following warning is printed on the box of nilutamide and should also be heeded when taking RU58841:

    "ALERT: U.S. Boxed Warning
    Interstitial pneumonitis:

    Interstitial pneumonitis has been reported in 2% of patients in controlled clinical trials in patients exposed to nilutamide. A small study in Japanese patients showed that 17% of patients developed interstitial pneumonitis. Reports of interstitial changes, including pulmonary fibrosis that led to hospitalization and death, have been reported rarely in postmarketing. Symptoms included exertional dyspnea, cough, chest pain, and fever. X-rays showed interstitial or alveolo-interstitial changes, and pulmonary function tests revealed a restrictive pattern with decreased diffusing capacity of lungs for carbon monoxide. Most cases occurred within the first 3 months of treatment with nilutamide, and most reversed with discontinuation of therapy. Perform a routine chest x-ray prior to initiating treatment with nilutamide. Consider baseline pulmonary function tests. Instruct patients to report any new or worsening shortness of breath that they experience while on nilutamide. If symptoms occur, immediately discontinue nilutamide until it can be determined if the symptoms are drug related."

    More information of this condition and it's treatment outcomes can be found at the following link:

    https://www.ncbi.nlm.nih.gov/pmc/art...00368-0046.pdf

Similar Threads

  1. Warning with Finasteride and Cancer
    By Paolo in forum Hair Loss Treatments
    Replies: 2
    Last Post: 11-10-2020, 04:12 AM
  2. [WARNING] Australia Scammers
    By Hair Bear in forum Men's Hair Loss: Start Your Own Topic
    Replies: 0
    Last Post: 04-29-2014, 06:18 AM
  3. Warning to those considering HASCI
    By JJJJrS in forum Techniques in Possible Donor Regeneration and Multiplication
    Replies: 2
    Last Post: 03-21-2014, 06:16 PM
  4. this forum should have sticked Warning
    By Scientalk56 in forum Cutting Edge / Future Treatments
    Replies: 0
    Last Post: 12-06-2013, 04:02 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts

» IAHRS

hair transplant surgeons

» The Bald Truth

» Recent Threads

1800 graft repair case results by Dr. Lindsey
Yesterday 08:38 AM
Last Post By Dr. Lindsey
Yesterday 08:38 AM
Navigating the German Job Market as a Kenyan Citizen
11-04-2023 06:31 AM
Last Post By Keegan212
Yesterday 03:51 AM
DR HAKAN DOGANAY/ 4500 GRAFTS / Implanter Pen+FUE
03-26-2024 04:15 PM
Last Post By Hakan Doganay, MD
03-26-2024 04:15 PM
The Mane Event for Thursday, June 15th, 2023
06-15-2023 02:59 PM
Last Post By gisecit34
03-26-2024 08:05 AM